- Home
- MIRM vs BDJ Comparison
MIRM vs BDJ Comparison
Compare MIRM & BDJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- BDJ
- Stock Information
- Founded
- MIRM 2018
- BDJ 2005
- Country
- MIRM United States
- BDJ United States
- Employees
- MIRM N/A
- BDJ N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- BDJ Finance Companies
- Sector
- MIRM Health Care
- BDJ Finance
- Exchange
- MIRM Nasdaq
- BDJ Nasdaq
- Market Cap
- MIRM 1.9B
- BDJ 1.6B
- IPO Year
- MIRM 2019
- BDJ N/A
- Fundamental
- Price
- MIRM $44.50
- BDJ $9.02
- Analyst Decision
- MIRM Strong Buy
- BDJ
- Analyst Count
- MIRM 13
- BDJ 0
- Target Price
- MIRM $57.00
- BDJ N/A
- AVG Volume (30 Days)
- MIRM 340.6K
- BDJ 561.6K
- Earning Date
- MIRM 11-12-2024
- BDJ 01-01-0001
- Dividend Yield
- MIRM N/A
- BDJ 8.85%
- EPS Growth
- MIRM N/A
- BDJ N/A
- EPS
- MIRM N/A
- BDJ N/A
- Revenue
- MIRM $307,028,000.00
- BDJ N/A
- Revenue This Year
- MIRM $73.07
- BDJ N/A
- Revenue Next Year
- MIRM $27.98
- BDJ N/A
- P/E Ratio
- MIRM N/A
- BDJ N/A
- Revenue Growth
- MIRM 112.14
- BDJ N/A
- 52 Week Low
- MIRM $23.14
- BDJ $6.91
- 52 Week High
- MIRM $48.89
- BDJ $8.66
- Technical
- Relative Strength Index (RSI)
- MIRM 65.32
- BDJ 65.80
- Support Level
- MIRM $41.09
- BDJ $8.74
- Resistance Level
- MIRM $48.89
- BDJ $8.94
- Average True Range (ATR)
- MIRM 2.16
- BDJ 0.10
- MACD
- MIRM 0.57
- BDJ 0.02
- Stochastic Oscillator
- MIRM 59.09
- BDJ 98.65
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.